Ocular anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy

Rafael Simó, Jeffrey M. Sundstrom, David A. Antonetti

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Diabetic retinopathy is the leading cause of visual impairment and preventable blindness, and represents a significant socioeconomic cost for health care systems worldwide. Therefore, new approaches beyond current standards of diabetes care are needed. Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic narrative. In the Bench narrative, we provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy, the molecular characteristics of anti-VEGF agents currently used, and future perspectives and challenges in this area. In the Clinic narrative that follows our contribution, Cheung et al. provide an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)893-899
Number of pages7
JournalDiabetes care
Volume37
Issue number4
DOIs
StatePublished - Apr 2014

Fingerprint

Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Therapeutics
Macular Edema
Vision Disorders
Blindness
Standard of Care
Clinical Trials
Delivery of Health Care
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

@article{816092223e034727b709696fc362af57,
title = "Ocular anti-VEGF therapy for diabetic retinopathy: The role of VEGF in the pathogenesis of diabetic retinopathy",
abstract = "Diabetic retinopathy is the leading cause of visual impairment and preventable blindness, and represents a significant socioeconomic cost for health care systems worldwide. Therefore, new approaches beyond current standards of diabetes care are needed. Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic narrative. In the Bench narrative, we provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy, the molecular characteristics of anti-VEGF agents currently used, and future perspectives and challenges in this area. In the Clinic narrative that follows our contribution, Cheung et al. provide an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy.",
author = "Rafael Sim{\'o} and Sundstrom, {Jeffrey M.} and Antonetti, {David A.}",
year = "2014",
month = "4",
doi = "10.2337/dc13-2002",
language = "English (US)",
volume = "37",
pages = "893--899",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

Ocular anti-VEGF therapy for diabetic retinopathy : The role of VEGF in the pathogenesis of diabetic retinopathy. / Simó, Rafael; Sundstrom, Jeffrey M.; Antonetti, David A.

In: Diabetes care, Vol. 37, No. 4, 04.2014, p. 893-899.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ocular anti-VEGF therapy for diabetic retinopathy

T2 - The role of VEGF in the pathogenesis of diabetic retinopathy

AU - Simó, Rafael

AU - Sundstrom, Jeffrey M.

AU - Antonetti, David A.

PY - 2014/4

Y1 - 2014/4

N2 - Diabetic retinopathy is the leading cause of visual impairment and preventable blindness, and represents a significant socioeconomic cost for health care systems worldwide. Therefore, new approaches beyond current standards of diabetes care are needed. Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic narrative. In the Bench narrative, we provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy, the molecular characteristics of anti-VEGF agents currently used, and future perspectives and challenges in this area. In the Clinic narrative that follows our contribution, Cheung et al. provide an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy.

AB - Diabetic retinopathy is the leading cause of visual impairment and preventable blindness, and represents a significant socioeconomic cost for health care systems worldwide. Therefore, new approaches beyond current standards of diabetes care are needed. Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic narrative. In the Bench narrative, we provide an overview of the role of VEGF in the pathogenesis of diabetic retinopathy, the molecular characteristics of anti-VEGF agents currently used, and future perspectives and challenges in this area. In the Clinic narrative that follows our contribution, Cheung et al. provide an overview of the current evidence from clinical trials on anti-VEGF therapy for diabetic retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=84897830175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897830175&partnerID=8YFLogxK

U2 - 10.2337/dc13-2002

DO - 10.2337/dc13-2002

M3 - Review article

C2 - 24652720

AN - SCOPUS:84897830175

VL - 37

SP - 893

EP - 899

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -